BIODESIX INC (BDSX): Nasdaq/NYSE listing notice — Biodesix receives Nasdaq deficiency notice for bid price below $1.00 per share

BIODESIX INC

Nasdaq notified Biodesix on March 24, 2025 that bid price closed below $1.00 for 30 consecutive business days.
Company has 180 calendar days, until September 22, 2025, to regain compliance with minimum bid price rule.
To cure, closing bid price must be at least $1.00 for 10 consecutive business days before Compliance Date.
If not cured by Sep 22, may be eligible for additional 180-day period on Nasdaq Capital Market if other standards met.
Company may consider reverse stock split to increase bid price; no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BIODESIX INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

March 24, 2025, Biodesix, Inc. (the “Company”) received written notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock had closed below the minimum $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq rules, the Company has been provided an initial period of 180 calendar days, or until September 22

View on SEC.gov

Browse all listing & compliance notices →

BIODESIX INC filing history →

Source: SEC EDGAR

accession 0000950170-25-046748

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.